PA-KNOPP-BIOSCIENCES-LLC
21.11.2018 12:26:39 CET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference to be held in New York, NY on November 27-29.
Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, November 27th at 12:50 p.m. Eastern Time.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit knoppbio.com .
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005061/en/
Contact:
MEDIA INQUIRIES: James Heins james.heins@icrinc.com +1.646.277.8251
INVESTOR INQUIRIES: Stephanie Carrington stephanie.carrington@icrinc.com +1.646.277.1282
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Technology Prevails in China Patent Infringement Action Against Angelalign12.8.2026 02:47:00 CEST | Press release
Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products m
Entrepreneurs Invited to Apply for 2027 SPIE Startup Challenge11.8.2026 20:40:00 CEST | Press release
The competition will bring seven teams head-to-head in pursuit of $10,000 first prize Entrepreneurs around the world are invited to apply for a chance to pitch their optics or photonics technologies or products to a panel of expert judges at the 17th annual SPIE Startup Challenge. SPIE, the international society of optics and photonics, holds the competition at Photonics West every January, with multiple teams walking away with cash prizes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811090450/en/ Coalesenz won first prize for their hand-held, point-of-care coagulation analyzer at the SPIE Startup Challenge at Photonics West in January 2026. More than a simple pitch competition, the SPIE Startup Challenge is an entry point into the community of high-tech business development of new products in healthcare and deep tech, with an audience of experienced photonics innovators and investors. Cash prizes of $10,000, $5,000, a
The Aga Khan Museum Welcomes Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors11.8.2026 17:30:00 CEST | Press release
The Aga Khan Museum is pleased to announce the appointment of Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811597825/en/ Prince Aly Muhammad Aga Khan, board member, Aga Khan Museum Prince Aly Muhammad Aga Khan joins the Board with a deep commitment to arts and culture. He brings an international outlook shaped by working with the Aga Khan Foundation and Aga Khan Music Programme. Committed to advancing pluralism and cultural dialogue, Prince Aly brings a fresh perspective that will help guide the Museum as it continues to evolve, engage new audiences, and expand its impact both in Canada and internationally. Prince Aly is the son of His Late Highness Prince Karim Aga Khan IV and brother of His Highness Prince Rahim Aga Khan V. Joining him on the Board is Saira Bhojani, Partner at Torys LLP and one of Canada's leading tax lawyers. Ms. Bhojani is wid
Mouser Explores the Future of Quantum Computing and Its Potential to Transform Engineering11.8.2026 16:48:00 CEST | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the latest installment of its Empowering Innovation Together (EIT) technology series, A Quantum Leap in Computer Processing. This installment explores the emerging field of quantum computing and examines how the principles of quantum mechanics could unlock new computational capabilities for solving problems that remain difficult for conventional computing architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811222432/en/ Explore how quantum computing could help engineers address problems too complex for traditional systems. Unlike traditional computers, quantum computers leverage quantum-mechanical phenomena, such as superposition, entanglement, and interference, to perform calculations in fundamentally different ways. While today's quantum systems still face challe
Rehlko Expands Power Plus™ Connected-Services Capabilities, Enhancing Value Across Installed Base11.8.2026 15:15:00 CEST | Press release
Rehlko Power Plus™Delivers 24/7 Remote Monitoring, Advanced Diagnostics, and Fleet-Wide Asset Visibility to Critical Power Systems Rehlko, a global industrial energy resilience platform providing custom-engineered, integrated power solutions for mission-critical infrastructure worldwide, today announced the expanded capabilities of Rehlko Power Plus™ industrial remote monitoring. The cloud-based platform is designed to help customers reduce downtime, improve backup power reliability, and proactively manage critical power assets through real-time monitoring, alerts, diagnostics, and reporting. Rehlko Power Plus represents a meaningful expansion of Rehlko’s aftermarket capabilities and reinforces the company's strategy to deepen customer engagement across the asset lifecycle while growing its higher-value aftermarket business. As backup power systems become increasingly critical to business continuity, organizations need more than periodic inspections and reactive maintenance. Rehlko Pow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom